# Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

> **NCT07044336** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 700 (estimated)

## Conditions studied

- Endometrial Cancer
- Malignant Solid Tumour

## Interventions

- **DRUG:** Puxitatug Samrotecan
- **DRUG:** Doxorubicin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT07044336
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2028-01-20
- **Final completion:** 2029-07-17
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07044336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07044336, "Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07044336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*